Ribas, Antoni http://orcid.org/0000-0003-3669-8458
Algazi, Alain http://orcid.org/0000-0001-6576-4659
Ascierto, Paolo A. http://orcid.org/0000-0002-8322-475X
Butler, Marcus O. http://orcid.org/0000-0002-9840-7057
Chandra, Sunandana
Gordon, Michael
Hernandez-Aya, Leonel
Lawrence, Donald
Lutzky, Jose http://orcid.org/0000-0002-9503-2130
Miller, Wilson H. Jr
Campbell, Katie M. http://orcid.org/0000-0001-6491-4432
Delafont, Bruno
Marshall, Shannon
Mueller, Nancy
Robert, Caroline
Article History
Received: 29 May 2020
Accepted: 27 October 2020
First Online: 7 December 2020
Change Date: 12 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-25285-0
Competing interests
: A.R. has received honoraria from consulting with Amgen, BMS, Chugai, Genentech, Merck, Novartis, Roche and Sanofi, is/has been a member of the scientific advisory board and holds stock in Advaxis, Apricity, Arcus Biosciences, Bioncotech Therapeutics, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, IsoPlexis, Kite-Gilead, Lutris Pharma, Merus, PACT Pharma, Rgenix and Tango Therapeutics, and has received research funding from Agilent and BMS through SU2C. A.A. reports grants from AstraZeneca, GSK and Novartis, during the conduct of the study, consulting fees, travel support and stock options from OncoSec, stock options for consulting from Valitor, honoraria and research funding to UCSF from Regeneron, honoraria from Array, and grants in the form of research funding to UCSF from Acerta, Amgen, AstraZeneca, BMS, Dynavax, Genentech, Idera, Incyte, ISA, LOXO, Merck, Novartis, Pfizer, Sensei, Tessa. P.A.A. reports grants or personal fees for advisory/consultancy work and research funding from BMS, Roche-Genentech and Array, personal fees for advisory/consultancy work and travel support from MSD, personal fees for advisory/consultancy work from Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, NewLink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, and Nektar, and personal fees for consultancy work from Italfarmaco. M.B. reports he is contracted by his institute to complete work on this study for AstraZeneca, along with personal fees and honoraria for consultancy work from Merck, BMS, Novartis, Sanofi, Pfizer, Immunocore, Adaptimmune, and EMD Serono. S.C. has received honoraria from consulting with and/or has been a member of the scientific advisory board of BMS, Novartis, Array BioPharma, Regeneron, Sanofi-Genzyme, and Exicure. M.G. reports institutional research support from Medimmune, Merck, BMS, Amgen, Tesaro, Beigene, ABBVIE, Aeglea, Arcus, Astex, BluePrint, Calithera, CellDex, Corcept, Clovis, Eli Lilly, Endocyte, Five Prime, Genocea, Neon, Plexxicon, Revolution Medicine, Seattle Genetics, Serono, SynDevRx, and Tolero, and personal fees and institutional research support from Agenus, Imaging Endpoints, Tracon, Deciphera, and Salarius. L.H.-A. reports personal fees for study-related fees to institution from AstraZenaca, personal fees paid to institution for conduction of clinical trials from BMS, Merck, Amgen, Roche, Regeneron, Novartis, Immunocore, Merck-EMD, Corvus, Polynoma, Genentech. J.L. reports personal fees for advisory board consultancy/attendance from Castle, Array Pharmaceuticals and Kimera and personal fees for advisory board and speaker bureau work from Regeneron Pharmaceuticals. W.H.M. reports consultancy fees from BMS, Merck, Roche, Novartis, Amgen, and GSK. KMC is a shareholder in Geneoscopy LLC. B.D., S.M., and N.M. are all employees of AstraZeneca. C.R. has received honoraria from consulting with Amgen, BMS, MSD, Novartis, Roche, CureVac, Biother, Sanofi, Pierre Fabre, and Merck.